Press Release
AimedBio Receives FDA IND Clearance for FGFR3-Targeting ADC AMB302
2024.11.01
- - AimedBio’s FGFR3-targeting ADC candidate AMB302 has received IND clearance from the U.S. FDA.
- - The company plans to run a Phase 1 clinical trial in both South Korea and the United States, enrolling patients with solid tumors including bladder cancer and head and neck cancer.
- - The first patient dosing is expected in Q1 2025 across both countries.